Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$24.31 USD
-1.39 (-5.41%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $24.29 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Beam Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,190 | 1,078 | 966 | 300 | 92 |
Receivables | 0 | 0 | 300 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 21 | 15 | 7 | 9 | 3 |
Total Current Assets | 1,211 | 1,093 | 1,273 | 308 | 95 |
Net Property & Equipment | 125 | 116 | 84 | 39 | 24 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 11 | 15 | 14 | 18 | 18 |
Total Assets | 1,460 | 1,342 | 1,474 | 452 | 156 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 9 | 7 | 6 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 112 | 48 | 68 | 18 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 80 | 156 | 131 | 73 | 9 |
Total Current Liabilities | 206 | 224 | 213 | 102 | 29 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 110 | 202 | 262 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 14 | 37 | 8 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 302 |
Total Liabilities | 478 | 608 | 648 | 206 | 357 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 2,170 | 1,793 | 1,594 | 643 | 2 |
Retained Earnings | -1,190 | -1,057 | -768 | -398 | -203 |
Other Equity | 1 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 981 | 733 | 827 | 246 | -201 |
Total Liabilities & Shareholder's Equity | 1,460 | 1,342 | 1,474 | 452 | 156 |
Total Common Equity | 981 | 733 | 827 | 246 | -201 |
Shares Outstanding | 81.50 | 70.40 | 68.10 | 57.90 | NA |
Book Value Per Share | 12.04 | 10.42 | 12.14 | 4.24 | 0.00 |
Fiscal Year End for Beam Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1,190 | 1,015 | 1,073 | 1,059 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 21 | 24 | 22 | 24 |
Total Current Assets | NA | 1,211 | 1,040 | 1,095 | 1,083 |
Net Property & Equipment | NA | 125 | 128 | 128 | 122 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 11 | 11 | 17 | 11 |
Total Assets | NA | 1,460 | 1,291 | 1,354 | 1,332 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 7 | 14 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 112 | 42 | 38 | 38 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 80 | 163 | 154 | 157 |
Total Current Liabilities | NA | 206 | 220 | 210 | 220 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 110 | 125 | 156 | 172 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 6 | 13 | 14 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 478 | 512 | 542 | 571 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 2,170 | 2,113 | 2,049 | 1,915 |
Retained Earnings | NA | -1,190 | -1,333 | -1,237 | -1,154 |
Other Equity | NA | 1 | -2 | -2 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 981 | 779 | 812 | 762 |
Total Liabilities & Shareholder's Equity | NA | 1,460 | 1,291 | 1,354 | 1,332 |
Total Common Equity | 0 | 981 | 779 | 812 | 762 |
Shares Outstanding | 81.60 | 81.50 | 79.20 | 76.20 | 74.60 |
Book Value Per Share | 0.00 | 12.04 | 9.84 | 10.65 | 10.21 |